EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma

Inclusion Criteria:

* Histologically-confirmed intracranial glioblastoma or gliosarcoma (World Health Organization \[WHO\] grade IV) with evidence of clinical and radiographic (computed tomography \[CT\] or MRI brain) tumor progression (need not be biopsy proven)
* Patients who have undergone prior resection, radiation therapy, and/or chemotherapy (except bevacizumab)
* Karnofsky performance score \>= 70 or Eastern Cooperative Oncology Group (ECOG) performance status = 0 or 1
* Patient agrees to undergo a baseline and a follow-up 11C-alpha-methyl-L-tryptophan (AMT)-PET scan during immunotherapy (IMT)
* No serious medical or psychiatric illness which prevents informed consent or intensive treatment is allowed
* Non pregnant: negative serum test for pregnancy, unless male, prior hysterectomy, tubal ligation, or postmenopausal; (Note: postmenopausal is defined as age \> 55 with amenorrhea for \> 1 year or age \< 55 years with amenorrhea for 2 years and follicle stimulating hormone (FSH) level within postmenopausal range of institutional parameters; patients requiring FSH level to determine menopausal status need not have this performed and may choose to proceed with serum pregnancy testing)
* Required initial laboratory data (normal limits per treating institution; minor changes from the indicated laboratory guidelines will be allowed at the discretion of the treating team under special circumstances and reasons for the changes will be documented):
* Granulocytes \>= 1,000/mm\^3
* Absolute lymphocyte count \>= 500/mm\^3
* Platelet count \>= 50,000/ul
* Hemoglobin \>= 8 gm/dl
* Blood urea nitrogen (BUN) =\< 1.5 times normal
* Serum creatinine \< 1.8 mg/dl
* Creatinine clearance \>= 50 ml/mm (can be calculated utilizing the Cockcroft \& Gault equation)
* Bilirubin \< 1.5 times upper limit of normal
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 5 times upper limit of normal
* Alkaline phosphatase \< 5 times upper limit of normal
* Prothrombin time (PT) or international normalized ratio (INR) and activated partial thromboplastin time (aPTT) \< 1.2 times upper limit of normal
* Negative human immunodeficiency virus (HIV)-1/2 serology
* Negative hepatitis B surface antigen
* Negative hepatitis C serology
* Left ventricular ejection fraction (LVEF) \>= 45% at rest (multi gated acquisition \[MUGA\] or echocardiogram \[ECHO\])
* Each patient must be aware of the nature of their disease and must willingly consent to treatment after being informed of alternatives, potential benefits, side effects, and risks
* Surgery is done prior to IMT if needed for palliation, tumor debulking, pathological documentation of tumor recurrence; the patients may continue on study therapy even if they do not have measurable disease
* No other investigational agents, immunomodulating agents, or cancer chemotherapy are permitted for the duration and 12 months following the study IMT unless there is disease progression; radiotherapy is not permitted; appropriate antibiotics, blood products, antiemetics, fluids, electrolytes and general supportive care are to be used as necessary

Exclusion Criteria:

* Resective surgery within 2 months prior to the initial pre-treatment AMT-PET scan
* Severe increased intracranial pressure, status epilepticus, or other serious complications from the brain tumor, requiring emergency or urgent intervention
* Patients with a history of another malignancy within 5 years of study enrollment
* Patients with extracranial metastases
* Evidence of active bleeding or bleeding diathesis
* Patients will be ineligible for treatment on this protocol if (prior to protocol entry):

  * There is a history of a recent (within one year) myocardial infarction
  * There is a current or prior history of angina/coronary symptoms requiring medications and/or evidence of depressed left ventricular function (LVEF \< 45% by MUGA or ECHO)
  * There is clinical evidence of congestive heart failure requiring medical management (irrespective of MUGA or ECHO results)